腺结合病毒（AAV）载体生产市场－全球产业规模、份额、趋势、机会及预测（按营运规模、方法、治疗领域、应用、地区及竞争格局划分，2021-2031年）

全球腺结合病毒（AAV）载体生产市场预计将从 2025 年的 14.8 亿美元成长到 2031 年的 29.8 亿美元，复合年增长率为 12.37%。

腺相关病毒（AAV）载体源自非致病性细小病毒，可作为人工病毒递送系统，将治疗性遗传物质导入宿主细胞，用于治疗遗传性疾病。市场扩张的关键驱动因素是慢性病盛行率的不断上升以及基因疗法监管核准的日益增多，而基因疗法需要大规模的商业化生产能力。这些根本因素并非暂时的市场趋势，而是对治疗药物供应和供应链可靠性的长期需求。

然而，该产业在生产扩充性面临着巨大的挑战，尤其是在实现高病毒滴度和有效去除纯化过程中的空衣壳方面，技术难度较高。随着临床专案推进到商业化产品阶段，这项生产瓶颈为供应链带来了复杂的难题。据美国基因与细胞治疗学会（ASGCT）称，该领域已取得重大里程碑式进展，预计将有七种新型细胞和基因治疗产品在2024年获得FDA核准。这些治疗方法的商业化进程不断加快，给现有的生产基础设施带来了巨大压力，使其难以维持稳定且经济高效的供应。

市场驱动因素

基于腺相关病毒（AAV）的基因治疗临床研发管线不断扩展，需要可扩展的生产能力来支援后期临床试验和商业化部署，从而推动市场扩张。随着候选疗法从药物发现进入监管审批阶段，对高品质病毒载体的需求日益增长，迫切需要解决上游工程的产量限制问题。监管核准前景的乐观也印证了这项发展势头。根据Oribiotech Ltd于2025年初发布的《再生医学联盟2025年第一季趋势》报告，有六种治疗方法被确定为2025年或2026年FDA加速核准途径的候选疗法。此外，一些拥有前景广阔的载体资产的公司也正在获得大规模投资。例如，AAVantgarde Bio公司在B轮资金筹措中筹集了1.41亿美元，用于推进其AAV基因增强计画（Vestbee，《2025年11月欧洲主要资金筹措轮次结束》，2025年12月版）。

同时，对合约研发生产机构（CDMO）日益增长的策略依赖正在改变供应链结构。生物製药公司经常将生产外包给专业合作伙伴，以避免建立内部基础设施相关的资本风险，并利用其在衣壳生产方面的技术专长。 2025年10月纳斯达克一篇题为《牛津生物医药公司以450万美元收购北卡罗来纳州基因治疗工厂》的报导重点介绍了这种产能整合趋势。该公司收购了北卡罗来纳州一家商业规模的病毒载体生产工厂，以增强其腺相关病毒（AAV）服务能力。这种依赖性使创新者能够专注于进行临床试验，同时利用CDMO的专业工业规模资源。

市场挑战

全球腺结合病毒（AAV）载体生产市场面临的主要障碍是生产扩充性不足，这主要是由于难以获得高病毒滴度和有效去除空衣壳等技术难题造成的。随着研发人员将候选疗法从临床试验过渡到商业化生产，现有生产平台往往无法在不增加过多成本的情况下维持所需的产量和纯度标准。这种技术效率低下造成了严重的生产瓶颈，导致供不应求和销货成本上升，最终限制了可整合到医疗保健系统中的治疗方法数量。

无法有效扩大生产规模正在阻碍市场成长，导致製造商无法满足日益增长的载体需求。有限的生产能力与不断扩大的开发平臺之间的差距日益凸显。根据美国基因与细胞治疗学会2024年第三季报告，全球基因、细胞和RNA疗法的研发管线已扩展至4,000多个候选药物。目前的基础设施不足以支持如此庞大的潜在商业产品数量，从而抑制了AAV载体生产行业的盈利能力和整体增长势头。

市场趋势

从贴壁培养系统转向悬浮培养系统的转变，正从根本上改变AAV的生产方式，显着提升商业性产量。製造商正迅速以悬浮培养平台取代劳力密集的贴壁培养技术，从而实现生物反应器内的规模化生产。 Forge Biologics公司在2024年10月发布的「FUEL AAV生产平台」新闻稿中详细介绍了这一转变，该平台推出了一种新型悬浮培养生产平台，其生产效率比行业标准提高了2-6倍。这些创新使研发人员能够克服传统方法的产能限制，并高效生产高效价病毒载体，以满足后期临床试验日益增长的需求。

同时，人工智慧驱动的衣壳设计与製程优化相结合，正在革新载体工程，以应对组织标靶化和免疫抗原性的挑战。开发人员正在利用机器学习演算法分析庞大的衣壳变体库，并设计具有增强递送特性的合成载体。这一趋势吸引了大量资本投资。根据Dyno Therapeutics于2024年10月发布的新闻稿《Dyno Therapeutics与罗氏建立新的战略联盟》，该公司签署了一项协议，利用其人工智慧驱动的平台进行下一代载体设计。该协议包括5000万美元的首付款，以及超过10亿美元的潜在里程碑付款。借助这些计算工具，市场正在从天然血清型向优化载体发展，从而提高治疗效果和生产效率。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球腺结合病毒（AAV）载体生产市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依营运规模（临床、临床前、商业化）
  • 依方法（体外、体内）
  • 依治疗领域（血液疾病、感染疾病、遗传性疾病、神经系统疾病、眼科疾病、其他）
  • 依应用领域（细胞疗法、基因疗法、疫苗）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美腺结合病毒（AAV）载体生产市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲腺结合病毒（AAV）载体生产市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区腺结合病毒（AAV）载体生产市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲腺结合病毒（AAV）载体生产市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美腺结合病毒（AAV）载体生产市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

13. 全球腺结合病毒（AAV）载体生产市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Catalent
• Lonza
• Thermo Fisher Scientific
• WuXi AppTec
• Charles River Laboratories
• AGC Biologics
• Novasep
• Vectalys
• uniQure

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Adeno-Associated Virus (AAV) Vector Manufacturing Market is projected to expand from USD 1.48 Billion in 2025 to USD 2.98 Billion by 2031, registering a CAGR of 12.37%. AAV vectors act as engineered viral delivery systems derived from non-pathogenic parvoviruses, designed to transport therapeutic genetic material into host cells to treat genetic disorders. Market expansion is primarily propelled by the growing prevalence of chronic diseases and a rise in regulatory approvals for gene therapies, which necessitate substantial commercial production capabilities. These foundational drivers are distinct from temporary market trends, creating a long-term requirement for therapeutic availability and supply chain reliability.

However, the industry faces significant hurdles regarding manufacturing scalability, specifically due to the technical complexities involved in reaching high viral titers and effectively removing empty capsids during purification. This production bottleneck creates complications within the supply chain as clinical programs evolve into commercial products. According to the American Society of Gene & Cell Therapy, the sector reached a major milestone in 2024 with the FDA approval of seven new cell and gene therapy products. This increase in commercialized therapies exerts considerable strain on current manufacturing infrastructure to maintain a consistent and cost-efficient supply.

Market Driver

The growth of the AAV-based gene therapy clinical pipeline stimulates market expansion by demanding scalable production capacities to sustain late-stage trials and commercial rollouts. As therapeutic candidates advance from the discovery phase to regulatory review, the requirement for high-quality viral vectors increases, intensifying the need to resolve upstream yield constraints. This momentum is highlighted by the strong array of expected regulatory outcomes; according to Oribiotech Ltd, citing the 'Alliance for Regenerative Medicine's Q1 2025 trends' report published in early 2025, six therapies were identified as candidates for the FDA's Accelerated Approval pathway in 2025 or 2026. Additionally, substantial investment is targeting companies with promising vector assets, as demonstrated when AAVantgarde Bio raised $141 million in Series B funding to progress its AAV gene-augmentation programs, according to Vestbee's 'Top European funding rounds closed in November 2025' report from December 2025.

Simultaneously, the increasing strategic dependence on Contract Development and Manufacturing Organizations (CDMOs) is transforming the supply chain structure. Biopharmaceutical firms are frequently outsourcing to specialized partners to avoid the capital risks associated with constructing internal infrastructure and to utilize technical expertise in capsid production. This shift toward capacity consolidation was emphasized when, according to a Nasdaq article from October 2025 titled 'Oxford Biomedica Acquires $4.5 Mln North Carolina Gene Therapy Facility,' Oxford Biomedica purchased a commercial-scale viral vector manufacturing site in North Carolina to specifically bolster its AAV service offerings. This reliance enables innovators to concentrate on clinical execution while capitalizing on the dedicated industrial-scale resources of CDMOs.

Market Challenge

The principal obstacle hindering the Global Adeno-Associated Virus (AAV) Vector Manufacturing Market is the deficiency in manufacturing scalability, stemming from the technical difficulties in attaining high viral titers and effectively eliminating empty capsids. As developers move therapeutic candidates from clinical trials to commercial-scale operations, existing production platforms often fail to sustain required yield and purity standards without incurring excessive costs. This technical inefficiency generates a significant production bottleneck, leading to supply shortages and increased costs of goods sold, which ultimately limits the number of therapies that can be successfully commercialized and integrated into healthcare systems.

This failure to scale production efficiently impedes market growth, preventing manufacturers from meeting the rising demand for vector supplies. The gap between restricted manufacturing capacity and the widening development pipeline is becoming increasingly distinct. According to the American Society of Gene & Cell Therapy's Q3 2024 report, the global pipeline for gene, cell, and RNA therapies has grown to encompass over 4,000 candidates in development. Current infrastructure is insufficient to support this massive volume of potential commercial products, thereby suppressing the revenue potential and overall growth trajectory of the AAV vector manufacturing sector.

Market Trends

The shift from adherent to suspension cell culture systems is fundamentally transforming AAV production by facilitating higher commercial yields. Manufacturers are swiftly replacing labor-intensive adherent techniques with suspension-based platforms that enable scalability within bioreactors. This transition was illustrated when Forge Biologics launched a new suspension-based manufacturing platform in October 2024, as detailed in their 'Forge Biologics Announces the FUEL AAV Manufacturing Platform' press release, which is capable of delivering a 2-6x increase in productivity over industry norms. Such innovations enable developers to surpass the volume constraints of traditional methods, ensuring that high-titer viral vectors can be produced efficiently to satisfy the rising requirements of late-stage clinical trials.

Concurrently, the integration of Artificial Intelligence for capsid design and process optimization is revolutionizing vector engineering to tackle challenges related to tissue targeting and immunogenicity. Developers are utilizing machine learning algorithms to analyze extensive libraries of capsid variants, engineering synthetic vectors with enhanced transduction profiles. This trend drew substantial capital investment when, according to a Dyno Therapeutics press release from October 2024 titled 'Dyno Therapeutics Forms New Strategic Partnership With Roche,' the company finalized a deal involving a $50 million upfront payment and potential milestones surpassing $1 billion to utilize its AI-driven platform for designing next-generation vectors. By employing these computational tools, the market is advancing beyond naturally occurring serotypes toward optimized vehicles that improve therapeutic efficacy and manufacturability.

Key Market Players

• Catalent
• Lonza
• Thermo Fisher Scientific
• WuXi AppTec
• Charles River Laboratories
• AGC Biologics
• Novasep
• Vectalys
• uniQure

Report Scope

In this report, the Global Adeno-Associated Virus (AAV) Vector Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Scale of Operation

• Clinical
• Preclinical
• Commercial

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Method

• In Vitro
• In Vivo

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Therapeutics Area

• Hematological Diseases
• Infectious Diseases
• Genetic Disorders
• Neurological Disorders
• Ophthalmic Disorders
• Others

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Application

• Cell Therapy
• Gene Therapy
• Vaccine

Adeno-Associated Virus (AAV) Vector Manufacturing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Adeno-Associated Virus (AAV) Vector Manufacturing Market.

Available Customizations:

Global Adeno-Associated Virus (AAV) Vector Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Scale of Operation (Clinical, Preclinical, Commercial)
  • 5.2.2. By Method (In Vitro, In Vivo)
  • 5.2.3. By Therapeutics Area (Hematological Diseases, Infectious Diseases, Genetic Disorders, Neurological Disorders, Ophthalmic Disorders, Others)
  • 5.2.4. By Application (Cell Therapy, Gene Therapy, Vaccine)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Scale of Operation
  • 6.2.2. By Method
  • 6.2.3. By Therapeutics Area
  • 6.2.4. By Application
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Scale of Operation
      • 6.3.1.2.2. By Method
      • 6.3.1.2.3. By Therapeutics Area
      • 6.3.1.2.4. By Application
  • 6.3.2. Canada Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Scale of Operation
      • 6.3.2.2.2. By Method
      • 6.3.2.2.3. By Therapeutics Area
      • 6.3.2.2.4. By Application
  • 6.3.3. Mexico Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Scale of Operation
      • 6.3.3.2.2. By Method
      • 6.3.3.2.3. By Therapeutics Area
      • 6.3.3.2.4. By Application

7. Europe Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Scale of Operation
  • 7.2.2. By Method
  • 7.2.3. By Therapeutics Area
  • 7.2.4. By Application
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Scale of Operation
      • 7.3.1.2.2. By Method
      • 7.3.1.2.3. By Therapeutics Area
      • 7.3.1.2.4. By Application
  • 7.3.2. France Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Scale of Operation
      • 7.3.2.2.2. By Method
      • 7.3.2.2.3. By Therapeutics Area
      • 7.3.2.2.4. By Application
  • 7.3.3. United Kingdom Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Scale of Operation
      • 7.3.3.2.2. By Method
      • 7.3.3.2.3. By Therapeutics Area
      • 7.3.3.2.4. By Application
  • 7.3.4. Italy Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Scale of Operation
      • 7.3.4.2.2. By Method
      • 7.3.4.2.3. By Therapeutics Area
      • 7.3.4.2.4. By Application
  • 7.3.5. Spain Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Scale of Operation
      • 7.3.5.2.2. By Method
      • 7.3.5.2.3. By Therapeutics Area
      • 7.3.5.2.4. By Application

8. Asia Pacific Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Scale of Operation
  • 8.2.2. By Method
  • 8.2.3. By Therapeutics Area
  • 8.2.4. By Application
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Scale of Operation
      • 8.3.1.2.2. By Method
      • 8.3.1.2.3. By Therapeutics Area
      • 8.3.1.2.4. By Application
  • 8.3.2. India Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Scale of Operation
      • 8.3.2.2.2. By Method
      • 8.3.2.2.3. By Therapeutics Area
      • 8.3.2.2.4. By Application
  • 8.3.3. Japan Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Scale of Operation
      • 8.3.3.2.2. By Method
      • 8.3.3.2.3. By Therapeutics Area
      • 8.3.3.2.4. By Application
  • 8.3.4. South Korea Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Scale of Operation
      • 8.3.4.2.2. By Method
      • 8.3.4.2.3. By Therapeutics Area
      • 8.3.4.2.4. By Application
  • 8.3.5. Australia Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Scale of Operation
      • 8.3.5.2.2. By Method
      • 8.3.5.2.3. By Therapeutics Area
      • 8.3.5.2.4. By Application

9. Middle East & Africa Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Scale of Operation
  • 9.2.2. By Method
  • 9.2.3. By Therapeutics Area
  • 9.2.4. By Application
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Scale of Operation
      • 9.3.1.2.2. By Method
      • 9.3.1.2.3. By Therapeutics Area
      • 9.3.1.2.4. By Application
  • 9.3.2. UAE Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Scale of Operation
      • 9.3.2.2.2. By Method
      • 9.3.2.2.3. By Therapeutics Area
      • 9.3.2.2.4. By Application
  • 9.3.3. South Africa Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Scale of Operation
      • 9.3.3.2.2. By Method
      • 9.3.3.2.3. By Therapeutics Area
      • 9.3.3.2.4. By Application

10. South America Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Scale of Operation
  • 10.2.2. By Method
  • 10.2.3. By Therapeutics Area
  • 10.2.4. By Application
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Scale of Operation
      • 10.3.1.2.2. By Method
      • 10.3.1.2.3. By Therapeutics Area
      • 10.3.1.2.4. By Application
  • 10.3.2. Colombia Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Scale of Operation
      • 10.3.2.2.2. By Method
      • 10.3.2.2.3. By Therapeutics Area
      • 10.3.2.2.4. By Application
  • 10.3.3. Argentina Adeno-Associated Virus (AAV) Vector Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Scale of Operation
      • 10.3.3.2.2. By Method
      • 10.3.3.2.3. By Therapeutics Area
      • 10.3.3.2.4. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Adeno-Associated Virus (AAV) Vector Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Catalent
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza
• 15.3. Thermo Fisher Scientific
• 15.4. WuXi AppTec
• 15.5. Charles River Laboratories
• 15.6. AGC Biologics
• 15.7. Novasep
• 15.8. Vectalys
• 15.9. uniQure

16. Strategic Recommendations

17. About Us & Disclaimer